دورية أكاديمية
Neutrophil to lymphocyte ratio as a prognosis biomarker of PRRT in NET patients.
| العنوان: | Neutrophil to lymphocyte ratio as a prognosis biomarker of PRRT in NET patients. |
|---|---|
| المؤلفون: | de Lima BAM; Nuclear Medicine Section, Brazilian National Cancer Institute-INCA, Rio de Janeiro, Brazil., da Silva RG; Abdominopelvic Surgery Section, Brazilian National Cancer Institute-INCA, Rio de Janeiro, Brazil., Carroll C; Abdominopelvic Surgery Section, Brazilian National Cancer Institute-INCA, Rio de Janeiro, Brazil.; Carbone Cancer Center, University of Wisconsin, Madison, WI, USA., Vilhena B; Clinical Oncology Section, Brazilian National Cancer Institute-INCA, Rio de Janeiro, Brazil., Perez C; Nuclear Medicine Section, Brazilian National Cancer Institute-INCA, Rio de Janeiro, Brazil., Felix R; Nuclear Medicine Section, Brazilian National Cancer Institute-INCA, Rio de Janeiro, Brazil., Carneiro M; Nuclear Medicine Section, Brazilian National Cancer Institute-INCA, Rio de Janeiro, Brazil., Neto LM; Nuclear Medicine Section, Brazilian National Cancer Institute-INCA, Rio de Janeiro, Brazil., Vaisman F; Endocrine Oncology Unit, Brazilian National Cancer Institute-INCA, Rio de Janeiro, Brazil., Corbo R; Nuclear Medicine Section, Brazilian National Cancer Institute-INCA, Rio de Janeiro, Brazil.; Endocrine Oncology Unit, Brazilian National Cancer Institute-INCA, Rio de Janeiro, Brazil., Pujatti PB; Nuclear Medicine Section, Brazilian National Cancer Institute-INCA, Rio de Janeiro, Brazil., Bulzico D; Nuclear Medicine Section, Brazilian National Cancer Institute-INCA, Rio de Janeiro, Brazil. danielbulzico@gmail.com.; Endocrine Oncology Unit, Brazilian National Cancer Institute-INCA, Rio de Janeiro, Brazil. danielbulzico@gmail.com. |
| المصدر: | Endocrine [Endocrine] 2022 Oct; Vol. 78 (1), pp. 177-185. Date of Electronic Publication: 2022 Jul 13. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Humana Press Country of Publication: United States NLM ID: 9434444 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1559-0100 (Electronic) Linking ISSN: 1355008X NLM ISO Abbreviation: Endocrine Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Feb. 1996- : Totowa, NJ : Humana Press Original Publication: Houndsmills, Basingstoke, Hants, UK : Macmillan Press, c1994- |
| مواضيع طبية MeSH: | Neuroendocrine Tumors*/diagnosis , Neuroendocrine Tumors*/pathology , Neutrophils*, Biomarkers ; Humans ; Lymphocyte Count ; Lymphocytes/pathology ; Positron-Emission Tomography ; Prognosis ; Radionuclide Imaging ; Retrospective Studies |
| مستخلص: | Purpose: Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE is a palliative therapeutic option for advanced Neuroendocrine Tumors (NETs). Prognostic factors can predict long-term outcomes and determine response to therapy. Among those already explored, biomarkers from full blood count, including neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) has shown value for other solid tumors and for NETs patients submitted to other forms of therapy. However, its relation to PRRT response and patients' prognosis is still to be determined. Methods: Medical records from 96 patients submitted to PRRT between 2010 and 2017 were reviewed, median NLR and PLR were calculated from baseline flood blood count and dichotomized as high or low. Progression-free survival (PFS) and Overall Survival (OS) were calculated. Results: NLR and PLR median values were 1.8 and 123, respectively. Patients with low NLR had a significantly longer OS (estimated median of 77.5 months, 95% CI: 27.3-127.7) when compared to patients with high NLR (estimated median of 47.7 months, 95% CI: 34.7-60.8); p = 0.04. Patients with low NLR had a trend toward a longer median PFS when compared to patients with high NLR [estimated medians of 77 months (95% CI: 27.3-127.7), and 47.7 months, (95% CI: 34.7-60.7)], respectively, p = 0.08. Conclusion: Patients with advanced-stage NET with NLR higher than 1.8 have worse long term clinical outcomes after PPRT. Larger studies are needed to validate the optimal cutoff for this biomarker. (© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.) |
| References: | M. Fraenkel, M. Kim, A. Faggiano, W.W. de Herder, G.D. Valk, Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature. Endocrine-Related Cancer 21, 153–163 (2014). (PMID: 10.1530/ERC-13-0125) J. Hallet, C.H.L. Law, M. Cukier, R. Saskin, N. Liu, S. Singh, Exploring the rising incidence of neuroendocrine tumors: A population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer 121, 589–597 (2015). (PMID: 10.1002/cncr.29099) A.I. Vinik, C. Chaya, Clinical presentation and diagnosis of neuroendocrine tumors. Hematology/Oncology Clinics 30, 21–48 (2016). (PMID: 10.1016/j.hoc.2015.08.006) M. Fraenkel, M.K. Kim, A. Faggiano, G.D. Valk, Epidemiology of gastroenteropancreatic neuroendocrine tumours. Best Practice & Research Clinical Gastroenterology 26, 691–703 (2012). (PMID: 10.1016/j.bpg.2013.01.006) J.C. Yao, M. Hassan, A. Phan, C. Dagohoy, C. Leary, J.E. Mares, E.K. Abdalla, J.B. Fleming, J.N. Vauthey, A. Rashid, D.B. Evans, One hundred years after “carcinoid”: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. Journal of Clinical Oncology 26, 3063–3072 (2008). (PMID: 10.1200/JCO.2007.15.4377) J. Strosberg, G. El-Haddad, E. Wolin, A. Hendifar, J. Yao, B. Chasen, E. Mittra, P.L. Kunz, M.H. Kulke, H. Jacene, D. Bushnell, T.M. O’Dorisio, R.P. Baum, H.R. Kulkarni, M. Caplin, R. Lebtahi, T. Hobday, E. Delpassand, E. van Cutsem, A. Benson, R. Srirajaskanthan, M. Pavel, J. Mora, J. Berlin, E. Grande, N. Reed, E. Seregni, K. Öberg, M. Lopera Sierra, P. Santoro, T. Thevenet, J.L. Erion, P. Ruszniewski, D. Kwekkeboom, E. Krenning, Phase 3 trial of 177 lu-dotatate for midgut neuroendocrine tumors. New England Journal of Medicine 376, 125–135 (2017). (PMID: 10.1056/NEJMoa1607427) T. Miura, H. Ohtsuka, T. Aoki, S. Aoki, T. Hata, T. Takadate, S. Maeda, K. Ariake, K. Kawaguchi, K. Masuda, M. Ishida, M. Mizuma, K. Nakagawa, T. Morikawa, F. Fujishima, T. Kamei, H. Sasano, & M. Unno, Increased neutrophil–lymphocyte ratio predicts recurrence in patients with well-differentiated pancreatic neuroendocrine neoplasm based on the 2017 World Health Organization classification. BMC Surgey 21, 176 (2021). F. Ohlendorf, R.A. Werner, C. Henkenberens, T.L. Ross, H. Christiansen, F.M. Bengel, T. Derlin, Predictive and prognostic impact of blood-based inflammatory biomarkers in patients with gastroenteropancreatic neuroendocrine tumors commencing peptide receptor radionuclide therapy. Diagnostics 11, 504 (2021). (PMID: 10.3390/diagnostics11030504) D. Shinko, C.I. Diakos, S.J. Clarke, K.A. Charles, Cancer-related systemic inflammation: the challenges and therapeutic opportunities for personalized medicine. Clinical Pharmacology & Therapeutics 102, 599–610 (2017). (PMID: 10.1002/cpt.789) G.J.K. Guthrie, K.A. Charles, C.S.D. Roxburgh, P.G. Horgan, D.C. McMillan, S.J. Clarke, The systemic inflammation-based neutrophil-lymphocyte ratio: Experience in patients with cancer. Critical Reviews in Oncology/Hematology 88, 218–230 (2013). (PMID: 10.1016/j.critrevonc.2013.03.010) M.S. Cho, J. Bottsford-Miller, H.G. Vasquez, R. Stone, B. Zand, M.H. Kroll, A.K. Sood, V. Afshar-Kharghan, Platelets increase the proliferation of ovarian cancer cells. Blood 120, 4869–4872 (2012). (PMID: 10.1182/blood-2012-06-438598) F. Zhang, W. Gong, Prognostic value of the platelet-to-lymphocyte ratio in patients with melanoma: a meta-analysis. Targeted Oncology 10, 1116 (2020). J.L. Ethier, D. Desautels, A. Templeton, P.S. Shah, E. Amir, Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: A systematic review and meta-analysis. Breast Cancer Research 19, 2 (2017). (PMID: 10.1186/s13058-016-0794-1) H. Mandaliya, M. Jones, C. Oldmeadow, I.I.C. Nordman, Prognostic biomarkers in stage IV non-small cell lung cancer (NSCLC): Neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR), platelet to lymphocyte ratio (PLR) and advanced lung cancer inflammation index (ALI). Translational Lung Cancer Research 8, 886–894 (2019). (PMID: 10.21037/tlcr.2019.11.16) B. Yucel, N.A. Babacan, T. Kacan, A.A. Eren, M.F. Eren, S. Bahar, M.G. Celasun, M.M. Seker, Z. Hasbek, Survival analysis and prognostic factors for neuroendocrine tumors in Turkey. Asian Pacific Journal of Cancer Prevention 14, 6687–6692 (2013). (PMID: 10.7314/APJCP.2013.14.11.6687) T. Salman, S.N. Kazaz, U. Varol, U. Oflazoglu, I.T. Unek, Y. Kucukzeybek, A. Alacacioglu, E. Atag, H.S. Semiz, H. Cengiz, I. Oztop, M.O. Tarhan, Prognostic value of the pretreatment neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for patients with neuroendocrine tumors: an izmir oncology group study. Chemotherapy 61, 281–286 (2016). (PMID: 10.1159/000445045) D.J. Kwekkeboom, E.P. Krenning, R. Lebtahi, P. Komminoth, B. Kos-Kudła, W.W. de Herder, U. Plöckinger, G. Åkerström, B. Annibale, R. Arnold, E. Bajetta, J. Barkmanova, Y.J. Chen, F. Costa, A. Couvelard, J. Davar, G. Delle Fave, B. Eriksson, M. Falconi, D. Ferone, D. Gross, A. Grossman, B. Gustafsson, R. Hyrdel, D. Ivan, G. Kaltsas, R. Kianmanesh, G. Klöppel, U.P. Knigge, V. Lewington, A.M. McNicol, E. Mitry, O. Nilsson, K. Öberg, J. O’Connor, D. O’Toole, U.F. Pape, M. Papotti, M. Pavel, A. Perren, M. Platania, G. Rindi, P. Ruszniewski, R. Salazar, A. Scarpa, K. Scheidhauer, J.Y. Scoazec, A. Sundin, W. Szpak, B. Taal, P. Vitek, M.P. Vullierme, B. Wiedenmann, ENETS consensus guidelines for the standards of care in neuroendocrine tumors: Peptide receptor radionuclide therapy with radiolabeled somatostatin analogs. Neuroendocrinology 90, 220–226 (2009). J.J. Zaknun, L. Bodei, J. Mueller-Brand, M.E. Pavel, R.P. Baum, D. Hörsch, M.S. O’Dorisio, T.M. O’Dorisiol, J.R. Howe, M. Cremonesi, D.J. Kwekkeboom, The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging 40, 800–816 (2013). (PMID: 10.1007/s00259-012-2330-6) R.J. Hicks, D.J. Kwekkeboom, E. Krenning, L. Bodei, S. Grozinsky-Glasberg, R. Arnold, I. Borbath, J. Cwikla, C. Toumpanakis, G. Kaltsas, P. Davies, D. Hörsch, E. Tiensuu Janson, J. Ramage, ENETS consensus guidelines for the standards of care in neuroendocrine neoplasms: peptide receptor radionuclide therapy with radiolabelled somatostatin analogues. Neuroendocrinology 105, 295–309 (2017). A. Pozza, B. Pauletti, M. Scarpa, C. Ruffolo, N. Bassi, M. Massani, Prognostic role of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with midgut neuroendocrine tumors undergoing resective surgery. International Journal of Colorectal Disease 34, 1849–1856 (2019). (PMID: 10.1007/s00384-019-03356-5) I.M. Modlin, K.D. Lye, M. Kidd, A 5-decade analysis of 13,715 carcinoid tumors. Cancer 97, 934–959 (2003). (PMID: 10.1002/cncr.11105) B.G. Taal, O. Visser, Epidemiology of neuroendocrine tumours. Neuroendocrinology 80, 3–7 (2004). (PMID: 10.1159/000080731) U.F. Pape, U. Berndt, J. Müller-Nordhorn, M. Böhmig, S. Roll, M. Koch, S.N. Willich, B. Wiedenmann, Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours. Endocrine-Related Cancer 15, 1083–1097 (2008). (PMID: 10.1677/ERC-08-0017) J.R. Strosberg, E.M. Wolin, B.A. Chasen, M.H. Kulke, D.L. Bushnell, M.E. Caplin, R.P. Baum, T.J. Hobday, A.E. Hendifar, K. Oberg, M.L. Sierra, P.B. Ruszniewski, E. Krenning, First update on overall survival, progression-free survival, and health-related time-to-deterioration quality of life from the NETTER-1 study: 177Lu-Dotatate vs. high dose octreotide in progressive midgut neuroendocrine tumors. Journal of Clinical Oncology 36, 4099 (2018). (PMID: 10.1200/JCO.2018.36.15_suppl.4099) E.A. Aalbersberg, D.M.V. Huizing, I. Walraven, B.J. de Wit-Van Der Veen, H.R. Kulkarni, A. Singh, M.P.M. Stokkel, R.P. Baum, Parameters to predict progression-free and overall survival after peptide receptor radionuclide therapy: A multivariate analysis in 782 patients. The Journal of Nuclear Medicine 60, 1259–1265 (2019). (PMID: 10.2967/jnumed.118.224386) E.A.J. Casas, V.P. Núñez, M. del Carmen Mallón Araujo, M. del Carmen Pombo Pasín, M.G. Pumar, Á.R. Morell, U. Anido-Herranz, J.M.C. Agrícola, J.M. Cameselle-Teijeiro, A. Hilal, Evaluation of 177Lu-Dotatate treatment in patients with metastatic neuroendocrine tumors and prognostic factors. World Journal of Gastroenterology. World Journal of Gastroenterology 26, 1513–1524 (2020). (PMID: 10.3748/wjg.v26.i13.1513) F. Panzuto, S. Nasoni, M. Falconi, V.D. Corleto, G. Capurso, S. Cassetta, M. di Fonzo, V. Tornatore, M. Milione, S. Angeletti, M.S. Cattaruzza, V. Ziparo, C. Bordi, P. Pederzoli, G. Delle Fave, Prognostic factors and survival in endocrine tumor patients: Comparison between gastrointestinal and pancreatic localization. Endocrine-Related Cancer 12, 1083–1092 (2005). (PMID: 10.1677/erc.1.01017) D. Hanahan, R.A. Weinberg, Hallmarks of cancer: The next generation. Cell 144, 646–674 (2011). (PMID: 10.1016/j.cell.2011.02.013) F. Mariani, P. Sena, L. Roncucci, Inflammatory pathways in the early steps of colorectal cancer development. World Journal of Gastroenterology 20, 9716–9731 (2014). (PMID: 10.3748/wjg.v20.i29.9716) H. Zhan, J.Y. Ma, Q.C. Jian, Prognostic significance of pretreatment neutrophil-to-lymphocyte ratio in melanoma patients: A meta-analysis. Clinica Chimica Acta 484, 136–140 (2018). (PMID: 10.1016/j.cca.2018.05.055) A. Gaitanidis, D. Patel, N. Nilubol, A. Tirosh, S. Sadowski, E. Kebebew, Markers of systemic inflammatory response are prognostic factors in patients with pancreatic neuroendocrine tumors (PNETs): a prospective analysis. Annals of Surgical Oncology 25, 122–130 (2018). (PMID: 10.1245/s10434-017-6241-4) G. Luo, C. Liu, H. Cheng, K. Jin, M. Guo, Y. Lu, J. Long, J. Xu, Q. Ni, J. Chen, X. Yu, Neutrophil-lymphocyte ratio predicts survival in pancreatic neuroendocrine tumors. Oncology Letters 13, 2454–2458 (2017). (PMID: 10.3892/ol.2017.5716) Y. Zhou, D. Li, Y. Lin, M. Yu, X. Lu, Z. Jian, N. Na, B. Hou, Pretreatment hematologic markers as prognostic predictors of gastroenteropancreatic neuroendocrine tumors: A systematic review and meta-analysis. OncoTargets and Therapy 11, 2489–2496 (2018). (PMID: 10.2147/OTT.S152657) T. Grenader, M.E. Pavel, P.B. Ruszniewski, J.B. Ćwikła, A.T. Phan, M. Raderer, E. Sedláčková, G. Cadiot, E.M. Wolin, J. Capdevila, L. Wall, G. Rindi, X.M.T. Thanh, M.E. Caplin, I. Borbath, D. Ysebaert, P. Vítek, H. Grønbæk, A. Adenis, L. Buscail, G. Cadiot, S. Dominguez, M. Ducreux, C. Lombard-Bohas, E. Mitry, P. Ruszniewski, J.F. Seitz, N. Begum, I. Harsch, C. Schöfl, M. Weber, B. Wiedenmann, M. Mallath, K. Sambasivaiah, R. Saxena, E. Bajetta, A. Buonadonna, R. Buzzoni, R. Cannizzaro, A. Colao, C. de Angelis, P. Tomassetti, B. Kos-Kudła, T. Salek, J. Capdevila, G. Soler, J.M. Tabernero, H. Ahlman, M. Kjellman, G. Aithal, A. Anthoney, A. Grossman, J. Newell-Price, J. Ramage, N. Reed, A. Rees, W. Steward, M. Choti. Prognostic value of the neutrophil/lymphocyte ratio in enteropancreatic neuroendocrine tumors. AntiCancer Drugs 31, 216–222 (2020). |
| فهرسة مساهمة: | Keywords: Biomarker; Neuroendocrine tumor; Peptide-related radionuclide therapy; Survival |
| المشرفين على المادة: | 0 (Biomarkers) 0 (copper dotatate CU-64) |
| تواريخ الأحداث: | Date Created: 20220713 Date Completed: 20220916 Latest Revision: 20221023 |
| رمز التحديث: | 20221213 |
| DOI: | 10.1007/s12020-022-03133-5 |
| PMID: | 35829985 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1559-0100 |
|---|---|
| DOI: | 10.1007/s12020-022-03133-5 |